Allogene Therapeutics, Inc. has announced the selection of standard fludarabine and cyclophosphamide $(FC)$ as the lymphodepletion regimen for its ALPHA3 study. This study is evaluating cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma (LBCL). The decision was made in collaboration with the ALPHA3 Data and Safety Monitoring Board and Steering Committee, and following consultation with the U.S. Food and Drug Administration. This marks a strategic shift for Allogene, as the company will not include ALLO-647 in any trials open to enrollment or pipeline programs. Instead, Allogene will focus on advancing next-generation AlloCAR T product candidates utilizing the Dagger® Platform Technology, which aims to minimize or eliminate the need for standard lymphodepletion. This approach is being tested in the ALLO-316 TRAVERSE trial for advanced renal cell carcinoma, and the ALLO-329 RESOLUTION trial for autoimmune diseases. Results of the ALPHA3 study will be presented in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.